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Abstract
Background: MicroRNAs (miRNAs) are important regulators that play key roles in tumorigenesis and tumor progression. A
previous report has shown that let-7 family members can act as tumor suppressors in many cancers. Through miRNA array,
we found that let-7f was downregulated in the highly metastatic potential gastric cancer cell lines GC9811-P and SGC7901-
M, when compared with their parental cell lines, GC9811 and SGC7901-NM; however, the mechanism was not clear. In this
study, we investigate whether let-7f acts as a tumor suppressor to inhibit invasion and metastasis in gastric cancers.
Methodology/Principal: Real-time PCR showed decreased levels of let-7f expression in metastatic gastric cancer tissues and
cell lines that are potentially highly metastatic. Cell invasion and migration were significantly impaired in GC9811-P and
SGC7901-M cell lines after transfection with let-7f-mimics. Nude mice with xenograft models of gastric cancer confirmed
that let-7f could inhibit gastric cancer metastasis in vivo after transfection by the lentivirus pGCsil-GFP- let-7f. Luciferase
reporter assays demonstrated that let-7f directly binds to the 39UTR of MYH9, which codes for myosin IIA, and real-time PCR
and Western blotting further indicated that let-7f downregulated the expression of myosin IIA at the mRNA and protein
levels.
Conclusions/Significance: Our study demonstrated that overexpression of let-7f in gastric cancer could inhibit invasion and
migration of gastric cancer cells through directly targeting the tumor metastasis-associated gene MYH9. These data suggest
that let-7f may be a novel therapeutic candidate for gastric cancer, given its ability to reduce cell invasion and metastasis.
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Introduction
Gastric cancer (GC) is the most common gastrointestinal
malignancy in East Asia, Eastern Europe, and parts of Central
and South America, and is the second leading cause of cancer-
related deaths [1]. Widespread metastasis has been a major reason
for the dismal outcome of GC patients. Metastasis is a complex,
multi-step process whereby cancer cells migrate from the primary
neoplasm to a distant location [2]. The process starts when
primary tumor cells invade adjacent tissue, followed by cells
entering into the blood stream (intravasation), translocating
through the vasculature, exiting from blood vessels (extravasation)
into the surrounding tissue parenchyma, initiating micrometasta-
ses and finally proliferating to form macroscopic secondary tumors
[3]. One of the critical regulators that involved in this process is a
microRNA (miRNA) [4].
MicroRNAs (miRNAs) are a class of endogenous and small non-
coding regulatory RNAs, which regulate genes at the post-
transcriptional level [5]. Mature miRNAs can be transcribed by
RNA polymerase II and are generated from the sequential
processing of primary miRNA transcripts by Drosha and Dicer;
they then serve as posttranscriptional regulators of gene expression
through complementary base pairing to messenger RNAs [6].
Many reports show that miRNAs play key roles in various
biological processes, including cell differentiation, proliferation,
apoptosis, stress resistance, fat metabolism, tumorigenesis, and
tumor metastasis [7,8,9].
The let-7 family is a conserved family of miRNAs. Let-7 was
originally observed in the nematode Caenorhabditis elegans [10],
and fourteen members have been found to date [11]. Recently, the
expression levels of many let-7-family members were found to be
reduced in a variety of cancers. For example, let-7 is downreg-
ulated in lung cancer, melanoma, and head and neck squamous
carcinoma, while overexpression of let-7 can inhibit cancer cell
growth [12,13,14,15,16,17,18]. Several oncogenes, such as RAS,
MYC, and HMGA2, are direct targets of let-7 [19,20,21]. Let-7f is
one member of the let-7 family. Previous studies have shown that
let-7f is up-regulated in primary breast cancer and promotes
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18409angiogenesis [22]; downregulation in PAH [23] was caused by
chronic hypoxia or monocrotaline in rats, and the level was
decreased in plasma vesicles of NSCLC patients [24]. In addition,
let-7f can affect cell proliferation by targeting Kallikrein-related
peptidases (KLKs), a family of serine proteases that have been
shown to be dysregulated in several malignancies, including
ovarian cancer [25].
Our lab have previously identified a group of differentially
expressed miRNAs between GC9811 and GC9811-P cells through
high-profile microRNA chip analyses that contain let-7f [26].
During the further characterization of let-7f in various cancer cell
lines, we found that let-7f functions as a metastasis suppressor. The
enhanced expression of let-7f can suppress GC cell invasion and
migration in vitro and in vivo. By bioinformatics analysis, we
identified that MYH9, which encodes a myosin IIA heavy chain
involved in the promotion of cancer cell migration or invasion, as a
putative let-7f target. Subsequent experiments confirmed that let-
7f can downregulate myosin IIA expression by targeting the
39UTR of MYH9, which provides a possible target for GC
treatment.
Materials and Methods
Tissue collection
Primary gastric tumor tissues, adjacent non-tumor gastric tissues
and distant metastatic gastric tissues were obtained from patients
who underwent surgery at the Xijing Hospital of Digestive
Diseases in Xi’an, China. All samples were clinically and
pathologically shown to be correctly labeled. Patients offering
samples for the study signed informed consent forms.
Cell culture
The human gastric cancer cell lines GC9811, GC9811-P,
SGC7901-NM, SGC7901-M were conserved in our own
laboratory and were cultured in RPMI1640 (HyClone), supple-
mented with 10% fetal bovine serum (FBS; GIBCO ), 100 units/
ml penicillin, and 0.1 mg/ml streptomycin at 37uCi na
humidified 5% carbon dioxide incubator.
RNA extraction and real-time PCR
qRT-PCR was performed to determine the expression levels of
potential let-7f target genes. Total RNA was extracted from tissues
or cultured cells using TRIZOL reagent (Invitrogen Life
Technologies). Complementary DNA (cDNA) was generated by
using a TaqMan Reverse Transcription Kit (Applied Biosystems).
Real-time PCR analyses were performed with a TaqMan Micro-
RNA Assay kit (Applied Biosystems). Primer of let-7f was
purchased from Ambion(MI0000437). Primer of MYH9 sequence
was designed using Primer Express Software (Version 1.5). The
primer-MYH9 sequence :(Forward) 59AGAGCTCACGTGCCT-
CAACG39 (Reverse) 59TGACCACACAGAACAGGCCTG39.All
protocols were carried out according to the manufacturer’s
instructions. The expression level of let-7f was normalized to
5S(Forward:59GATTGAATCGAGCACCAGTTAC39;
Reverse: 59GTCTACGGCCATACCACCCTGAAC39). The
expression level of MYH9 was normalized to18S(Forward:59-
CGGCTACCACATCCAAGGAA39;
Reverse: 59GCTGGAATATCCGCGGCT39).PCR and data
collection were performed on an iCycler (Bio-Rad). Each sample
was run in triplicate.
Vector constructs and Lentivirus Production
The pri-let-7f sequence was constructed as follows: (Forward)
hsa-let-7f-1-Xho I-F GGGCCCGCTCTAGACTCGAGATATT-
TGCATGTCGCTATGTG, (Reverse) hsa-let-7f-1- BamH I-R
CGCGGCCGCCTAATGGATCCAAAAAAGGCACAGTCG-
AGGCTGATC. The sequence was amplified and cloned into the
pGCsil-GFP Vector (GENECHEM) to generate pGCsil-GFP- let-
7f. Negative control was pGC FU-RNAi-NC-LV. Virus packaging
was performed in HEK 293T cells after the cotransfection of
20 mg pGCsil-GFP-let-7f vector with 15 mg of the packaging
plasmid pHelper 1.0 Vector and 10 mg of the envelope plasmid
pHelper 2.0 Vector using Lipofectamine 2000 (Invitrogen).
Viruses were harvested 48 h after transfection, and viral titers
were determined.
Oligonucleotide construction
let-7f mimics, let-7f inhibitor and negative control siRNA
oligonucleotides were chemosynthesized (Shanghai GenePhama
Co., Ltd). The oligonucleotides used in these studies were has-let-
7f mimics: 59UGAGGUAGUAGAUUGUAUAGUU39and
59CUAUACAAUCUACCUCAUU39;
Mimics negative control: 59UUCUCCGAACGUGUCACGU-
T39and59ACGUGACACGUUCGGAGAATT39, has-let-7f in-
hibitor: 59AACUAUACAAUCUACUACCUCA39. MircoRNA
inhibitor negative control:59CAGUACUUUUGUGUAGUA-
CAA39.
Cell transfection
Cells were cultured to 80% to 90% confluence after being
seeded into 6-well plates and were transfected with Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. For transient transfection, cells in each well of a 6-well
plate were transfected with 12.5 ml miRNA inhibitor or 7.5 ml
miRNA mimic oligonucleotides. After 48 h of transfection, cells
were harvested for further experimentation. For stably transfected
cells, cells were transfected with lentivirus at 30%–50% con-
fluency. Target cells (1610
4), including GC 9811-P and
SGC7901-M cells, were infected with 1610
6 recombinant
lentivirus-transducing units in the presence of 6 mg/mL polybrene
(GENECHEM).
Invasion assay
The invasive ability of the cells was assayed using Transwells (8-
mm pore size, Corning Costar Corp). The Transwells were put into
the 24-well plates. First, 0.1 ml Matrigel(50 mg/ ml, BD
Biosciences) was added onto the plate surface and incubated for
2 h, and then the supernatant was removed. Freshly trypsinized
and washed cells (GC9811, GC9811-p, SGC7901-NM,
SGC7901-M) were suspended in RPMI1640 containing 1% fetal
bovine serum. Then 100 ml of the cell suspension (1610
5 cells) was
added to the upper chamber of each insert that was coated with
Matrigel. Next, 450 ml of RPMI1640 containing 10% fetal bovine
serum was added into the lower compartment, and the cells were
allowed to invade for 24 h–48 h at 37uC in a 5% CO2 humidified
incubator. After incubation, the cells were fixed with 95% absolute
alcohol and stained with crystal violet. Cells on the upper surface
of the filter were removed with the cotton swab and the cells that
had invaded into the bottom surface of the filter were counted and
imaged under an inverted microscope (Olympus Corp. Tokyo,
Japan) at 6200 magnification over ten random fields in each well.
Each experiment was performed in triplicate.
Cell migration
The ability of GC9811, GC9811-P, SGC7901-NM, and
SGC7901-M cells to migrate was detected using Transwells [8-
mm pore size, Corning Costar Corp]. The Transwells were put
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suspended in RPMI1640 containing 1% fetal bovine serum.
5610
4 cells /well were placed in the top chamber of each insert
(BD Biosciences, NJ), with the non-coated membrane. 450 mlo f
RPMI1640 containing 10% fetal bovine serum was added into the
lower chambers. After incubating for 24 h–48 h at 37uCi na5 %
CO2 humidified incubator, cells were fixed with 95% absolute
alcohol and stained with crystal violet. The cells in the inner
chamber were removed with a cotton swab and the cells attached
to the bottom side of the membrane were counted and imaged
under an inverted microscope (Olympus Corp. Tokyo, Japan) at
6200 magnification over ten random fields in each well. Each
experiment was performed in triplicate.
In Vivo metastasis assay
For the in vivo metastasis assays, the stable cell lines GC9811-P
and SGC7901-M were harvested from tissue culture flasks after
transfection with the lentivirus pGCsil-GFP- let-7f and control
pGCsil-GFP using trypsin and washed three times with PBS. Then
2610
6 cells were suspended in 0.2 ml serum-free RPMI1640 for
each mouse (six in each group, Fale BALB/c-nu/nu, 6–8 weeks
age), and the cells were injected into the tail vein. After four weeks
of injection, the mice were sacrificed. Liver tissue was observed
with the naked eye, and the number of visible tumors in the liver
surface was counted. The liver tissues were divided into serial
sections, fixed with phosphate-buffered neutral formalin, stained
with hematoxylin and eosin and examined histologically. Nude
mice were manipulated and cared for according to NIH Animal
Care and Use Committee guidelines in the Experiment Animal
Center of the Fourth Military Medical University (Xi’an, Shanxi
Province, P.R. China).
Luciferase Reporter Assay
To investigate whether MYH9 expression was regulated by let-
7f, a dual-luciferase reporter assay was performed. The 39 UTR of
MYH9 containing let-7f binding site was amplified by PCR.
Amplification of MYH9 used the following primers: (Forward)
XhoIF: 59CCGctcgagGCCTCTTCTCCTGCAGCCTG 39 (Re-
verse) NotIR: 59ATAAGAATgcggccgcTCGTAGCACATGGTT-
CTCTTTATTG 39
As a negative control, the mutated binding site of the 39-UTR
sequence (using the reverse complement of the binding site)
was amplified using the primers: (Forward) mutlet7MYH9F:
59TTGCAATCACACGTGGTGTGGAGTCACACCTCTGC-
CCCTTGG39 (Reverse) mutlet7MYH9R: 59CCAAGGGGCA-
GAGGTGTGACTCCACACCACGTGTGATTGCAA 39. Pro-
ducts were reclaimed via agarose gel electrophoresis, and cloned
into the luciferase reporter PsiCHECK vector (Promega, Madison,
Figure 1. Let-7f expression in gastric cancer tissues and cells measured by real-time PCR. (A) The mean fold-changes of let-7f gene
expression in GC9811 and GC9811-P(right). The mean fold-changes of let-7f gene expression in SGC7901-NM and SGC7901-M(left). Student’s t-test,
n=3. (B) The relative expression of let-7f to 5S. * P,0.05. ** P,0.01. one-way ANOVA, n=8. Real-time PCR show that the relative expression of let-7f
in eight adjacent non-cancerous gastric tissue samples, and in gastric cancer cell lines GC9811, SGC7901-NM is higher than that in their primary
gastric cancer and distant gastric metastasis specimens and the high potential metastasis gastric cancer cell GC9811-P and SGC7901-M.Each sample
was analyzed in triplicate and normalized to 5S. Fold change was calculated by 2-DDCt.
doi:10.1371/journal.pone.0018409.g001
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GC9811-P cells were seeded into 24-well plates and cotrans-
fected with Let-7f inhibitors or control, and luciferase reporters
using Lipofectamine
TM 2000 (Invitrogen), following the instruc-
tions. After 48 h of incubation, firefly and Renilla luciferase
activity was measured with the dual luciferase reporter assay
system (Promega).
Western Blot
Cells were washed twice with ice-cold PBS and scraped into
RIPA buffer (50 mM Tris–HCl pH 7.4, 1% (v/v) Triton X-100,
1 mM EDTA, 1 mM leupeptin, 1 mM phenylmethylsulfonyl
fluoride, 10 mM NaF, 1 mM Na3VO4) with freshly added
protease inhibitor cocktail (Roche) for 15 min on ice, then
centrifuged at 13,000 rpm for 10 min and the supernatants were
collected. Ten micrograms of each sample was resolved using 6%
SDS-PAGE and transferred onto a nitrocellulose membrane (Bio-
Rad, Hercules, CA). The bands were incubated with 10% nonfat
dry milk in Tris-buffered saline–0.1% Tween-20 to block the
nonspecific binding sites and incubated with a primary antibody:
rabbit polyclonal anti-human myosin IIA (diluted 1:500; Cell
Signaling Technology) overnight at 4uC. After rewarming and
repeated washing three times,15 min for each one, the membranes
were incubated with horseradish-peroxidase-conjugated anti-
rabbit secondary antibody (Santa Cruz Biotechnology), diluted
1:2000 for two hours at room temperature. The bands were
detected using an enhanced chemiluminescence system (Amer-
sham Biosciences).
Immunohistochemistry
Two tissue arrays were purchased from SHANXI CHAOY-
ING BIOTECHNOLOGY CO.,LTD. One was gastric cancer
tissue and matched adjacent normal stomach tissue, the other was
gastric cancer tissue and matched lymph node metastasis .Tissue
arrays were dewaxed in 60uC for 2 h, high temperature antigen
recovery for 10 mins, rehydrated, incubated in 10% normal goat
serum for 1 h, then incubated with rabbit polyclonal anti-human
myosin II A(diluted 1:100; Cell Signaling Technology) overnight
at 4uC. The slides were washed in PBS three times for 5 min
each. The tissues were incubated in goat anti-rabbit serum
(DAKO) for 1 h, rinsed with PBS. Sections were detected using
DAB and counterstained with hematoxylin. The staining intensity
was scored using a four step scale (0, 1+,2 +,o r3 +) and the
percentage of positive cells was estimated by three different
pathologists (0=none, 1=,1%, 2=1–10%, 3=10–30%,
4=30–70%, 5=.70% of tumor cells). Total average scores
were then grouped into four categories: negative (no detectable
staining when evaluated compared to nonspecific background
staining, weak (+), moderate(++)or strong (+++) and compared
using Mann-Whitney test.
Figure 2. Effect of let-7f on tumor cell invasion and metastasis of GC9811and GC9811-P Cells. (A) Invasion and migration assay.
Representative fields of invasive (up) or migration (down) cells on the membrane(left). (magnification of 6200). Average invasive or migration cell
number per field (right). The invasive or migration cell number of GC9811 cells transfected with let-7f-inhibitors is drastically increased than that
transfected with negative control. *P,0.05, Student’s t-test, n=10. (B). The invasive or migration cell number of GC9811-P Cells transfected with
let-7f-mimics is drastically decreased than that transfected with negative control. *P,0.05, Student’s t-test, n=10.
doi:10.1371/journal.pone.0018409.g002
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Student’s t-test (two-tailed), One-way ANOVA and Mann-
Whitney test were employed to analyze the in vitro and in vivo
data using SPSS 12.0 software (Chicago, IL, USA). P value,0.05
was defined as statistically significant. * P,0.05; **P,0.01.
Results
The level of let-7f expression was frequently decreased in
human GC metastatic cell lines and tissues
We have examined the mRNA expression levels of let-7f in two
pairs of human gastric cancer cell lines, GC9811, GC9811-P and
SGC7901-NM, SGC7901-M. As shown in Figure 1A, expression
of let-7f was lower in the GC cells, GC9811-P and SGC7901-M,
with high metastatic potential, while let-7f was more highly
expressed in the GC cells, GC9811 and SGC7901-NM, with low
metastatic potential. To further validate the role of let-7f in gastric
cancer cells metastasis, we compared the expression levels of let-7f
in fresh human gastric cancer tissue specimens with metastases
from eight individuals (Table S1), to normal gastric tissues (NG),
primary gastric cancer tissues (GC) and distant metastatic gastric
cancer tissues (MC), respectively, by real-time PCR. Intriguingly,
there was remarkable downregulation of let-7f in MC and GC,
compared to let-7f expression in NG (Figure 1B). We observed
that either the loss of or decreased expression of let-7f in tumors
and their metastatic tissues resulted in enhanced metastasis in
gastric cancer tissues. The results all suggested that the expression
of let-7f was negatively correlated very closely with decreased GC
metastases and might play a vital role in pathological processes.
We have thus provided clinical and cellular conceptual evidence
for a metastatic switch in cancer development that suggests a key
role for the expression of let-7f in cancer development.
Let-7f inhibited the invasive and metastatic abilities of
GC cells in vitro
Because let-7f acts as an agitator in invasion and metastatic
processes, we investigated the effects of decreased let-7f on less-
metastatic cell lines and increased let-7f on more-metastatic cell
lines. To accomplish this, short interfering RNA (siRNA)
oligonucleotides of let-7f were constructed and introduced into
GC9811 cells and SGC7901 -NM cells for metastasis assays in
vitro, as GC9811-let-7f-siRNA cells, SGC7901-NM-let-7f-siRNA
cells and control cells. Concurrently, mimic-let-7f and negative
control oligonucleotides were also constructed and introduced into
GC9811-P cells and SGC7901-M cells for metastasis assays in
vitro, as GC9811-P-let-7f-mimic cells, SGC7901-N-has let-7f-
mimic cells and control cells. Depletion of let-7f significantly
impaired the ability of GC9811 cells to migrate and invade
through the matrigel-coated membranes or the non-matrigel-
coated membranes towards serum-containing medium in a
modified Boyden chamber assay (Figure 2A). Increased expres-
sion of let-7f significantly suppressed the ability of GC9811-P cells
Figure 3. Effect of let-7f on tumor cell invasion, metastasis of SGC7901-NM and SGC7901-M cells. (A) Invasion and migration assay.
Representative fields of invasive (up) or migration (down) cells on the membrane(left). (magnification of 6200). Average invasive or migration cell
number per field (right). The invasive or migration cell number of SGC7901-NM transfected with let-7f-inhibitors is drastically increased than that
transfected with negative control. *P,0.05,Student’s t-test, n=10. (B) The invasive or migration cell number of SGC7901-M Cells transfected with
let-7f-mimics is dramatically decreased than that transfected with negative control. *P,0.05, Student’s t-test, n=10.
doi:10.1371/journal.pone.0018409.g003
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non-matrigel-coated membranes towards serum-containing medi-
um in a modified Boyden chamber assay (Figure 2B), when
compared with the control cells. Similar results were found in
SGC7901-NM cells (Figure 3A) and SGC7901-M cells
(Figure 3B), while let-7f knockout in GC cell lines resulted in
higher invasion and migration rates.
Let-7f inhibits tumor invasion and metastasis in a nude
mouse xenograft model
GC9811-P or SGC7901-M tumor cells transfected with the
lentivirus pGCsil-GFP- let-7f or negative control pGCsil-GFP
were injected into nude mice and the mice were sacrificed four
weeks after the inoculations. The number of metastatic nodi was
dramatically reduced in the nude mice injected with the pGCsil-
GFP- let-7f transfected cells, when compared to the negative
controls (Figure 4A, 4B). These data provide strong evidence that
let-7f can inhibit tumor invasion and metastasis in vivo.
Let-7f downregulates myosin IIA expression by directly
targeting its 39 UTR
To further explore the mechanism by which let-7f suppresses
GC invasion and metastasis, we analyzed potential downstream
tumor metastasis-related target genes in silico. We focused on let-
7f target genes, especially those genes that were migration and/or
invasion-related, and found that myosin IIA, involved in the
promotion of cancer cell migration or invasion, might be the target
gene of let-7f. In an effort to determine whether myosin IIA is
regulated by let-7f through direct binding to its 39 UTR, we
constructed full-length wild-type and mutant fragments of MYH9
mRNA 39 UTR, and inserted them into the region immediately
downstream of a luciferase reporter gene (Figure 5A). Subse-
quently, let-7f mimic oligos were co-transfected with different
luciferase 39 UTR constructs into GC9811-P cells. We found that
let-7f decreased the relative luciferase activity in the wild-type 39
UTR of MYH9 (Figure 5B). However, luciferase activity did not
drop sharply in the UTRs with mutant binding sites, when
compared to the mut-type counterparts (Figure 5C). These data
support that MYH9 is direct target of let-7f.
RT-PCR showed that the expression of MYH9 in GC9811
cells and SGC7901-NM cells transfected with let-7f-mimics is
downregulated compared to those cells transfected with control
constructs (Figure 5D). Western blotting results showed
expression of myosin IIA in GC9811 and SGC7901-NM cells
transfected with let-7f-mimics are down-regulated compared to
those transfected with negative control (Figure 5E). Furthmore,
Real-time PCR shows that mRNA relative expression of MYH9
in GC tissues and distant metastatic tissue are down-regulated
compared with their normal adjacent non-cancerous specimens
(Figure 6A). Immunohistochemistry showed that the expression
of myosin IIA in GC lymph node metastasis is up-regulated
compared with its primary GC tissue (Table 2; Figure 6C;
Figure S1B), and it is up-regulated in GC tissue compared with
its matched adjacent normal stomach tissue (Table 1;
Figure 4. In vivo metastasis assay. GC9811-P and SGC7901-M cells were transfected with lentivirus pGCsil-GFP-let-7f or negative-control lentivirus
pGCsil-GFP, and then injected into nude mice via the tail vein, as described in Materials and Methods. Animals were sacrificed 4 weeks after injection.
(A) Representative anatomical photos of lives from mice injected with GC9811-P- pGCsil-GFP or GC9811-P- pGCsil-GFP- let-7f(left). The mean number
of visible tumor nodules in liver (right). P,0.01. Student’s t-test, n=6. (B) Representative anatomical photos of lives from mice injected with SGC7901-
M - pGCsil-GFP or SGC7901-M - pGCsil-GFP- let-7f(left). The mean number of visible tumor nodules in liver(right). P,0.01. Student’s t-test, n=6.
doi:10.1371/journal.pone.0018409.g004
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down-regulate the mRNA expression of MYH9 and can repress
protein translation of it.
Discussion
In the present study, we demonstrated that let-7f expression in
metastatic GC cell lines was downregulated when compared to let-
7f expression in non-metastatic GC cells. Ectopic expression and
siRNA knockdown of let-7f confirmed its invasion-suppressing
activity in vitro and in vivo. Moreover, we show that MYH9 is a
direct target for let-7f and this let-7f mediated suppression of
MYH9 is dependent on its 39-UTR. Therefore, these results
highlight the significance of let-7f as a tumor suppressor in cell
invasion and metastasis by targeting MYH9 in gastric cancer.
Recent studies show that miRNAs may act as activators or
inhibitors of tumor metastasis [27]. For example, microRNA-10b
[28], miR-373 and miR-520c [29,30] stimulated cancer cell
migration and invasion in breast cancer. Additionally, miR-155
can promote tumor invasion and metastasis in breast cancer by
downregulating its target, RhoA [31] and promote tumor invasion
and metastasis in pancreas duct carcinoma by repressing the
expression of TP53INP1 [32]. The miRNA-200 family (miRNA-
200a, miRNA-200b, miRNA-200c, miRNA-141 and miRNA-
429) can inhibit tumor invasion and metastasis by regulating the
EMT [33]. MiR-126 was found to inhibit cell adhesion, migration
Figure 5. let-7f directly targets MYH9. (A) Predicted duplex formation between human MYH9 39UTR (top) and has-let-7f (bottom) and the
sequence of the let-7f-binding site within the MYH9 39UTR and mutant (mut) MYH9 39UTR. Luciferase activity of the MYH9 39UTR (B) or mut MYH9 (C)
39UTR reporter gene in GC9811 cells infected with the let-7f, let-7f-inhibitor, blank or empty mimic oligo. The assays showed that luciferase activities
in the group were significantly decreased compared to those of the mutant and negative control groups. * P,0.05. (D) The expression of MYH9 was
analyzed by qRT-PCR. MYH9 was decreased in GC9811 cells and SGC7901 cells transfected with let-7f-mimics compared to GC9811 cells and SGC7901
cells transfected with let-7f -negative control. (E) let-7f suppresses the endogenous protein levels of MYH9, as detected by Western blot. Stable
transduced SGC7901-NM and GC9811 cells ectopically expressing let-7f were used for Western blot analysis. Effect of let-7f on MYH9 in GC9811 cells
(top). Effect of let-7f on MYH9 in SGC7901-NM cells (bottom).
doi:10.1371/journal.pone.0018409.g005
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vitro model of non-small-cell lung carcinoma [34]. It has been
shown that miR-29c is significantly reduced in highly invasive and
metastatic nasopharyngeal carcinoma [35]. MiR-218 inhibits the
invasion and metastasis of gastric cancer by targeting the Robo1
receptor [26]. Although many studies have been done to
investigate the mechanism of miRNA and tumor metastasis, the
mechanism was not clear. Most importantly, few studies have been
done on the mechanisms of GC metastasis regulation by
microRNA.
The let-7f gene is located at 9q22.3, and is involved in a variety
of physiological and pathological processes, including angiogenesis
[36], immunocyte differentiation [37], replicative senescence [38],
growth arrest [39], pulmonary arterial hypertension and carcino-
genesis [23]. Let-7f is downregulated in several malignancies. A
highly characterized example is renal cell carcinoma, in which let-
7f downregulation led to a significant decrease in kallikrein (KLK)
expression [40]. KLKs can also be targeted by let-7f in ovarian
cancer [25]. In papillary thyroid cancer, reduced expression of let-
7f might be an essential molecular event in RET/PTC malignant
transformation [41]. In the case of primary breast cancer,
however, let-7f was upregulated when compared to normal
adjacent tumor tissues [22]. In our study, we demonstrated that
let-7f is also downregulated in MC tissues and GC cell lines with
high metastatic potential, and we further explored the mechanism
by which let-7f reduced tumor invasion and metastasis.
MYH9 is the gene for non-muscle myosin heavy chain IIA
(NMHCIIA), whose mutations are responsible for a complex
disorder named MYH9-related disease, characterized by a
combination of different phenotypic features [42]. NMMHC-
IIA, a 1960 amino acid polypeptide, with a translated molecular
weight of 220 kDa, is a conventional, non-sarcomeric myosin
expressed in most cells and tissues. Its functions include roles in
cytokinesis, cell motility, and maintenance of cell shape [43].
Many studies suggest that MYH9/NMHC-IIA has a key role in
tumor cell invasive behavior.For example, the EGF-dependent
phosphorylation of the myosin-IIA heavy chain has a direct role in
mediating motility and chemotaxis in MDA-MB-231 human
breast cancer cells [44]. Myosin IIA appears to be a major cellular
target of mts1 [45], the small calcium-binding protein metastasin-
1, and co-localizes with mts1 to the leading edge of migrating
cancer cells [46]; mts1 influences both the assembly behavior of
Figure 6. The expression of MYH9 in gastric tumor specimens. (A) Real-time PCR show that the relative expression of MYH9 in eight distant
gastric metastasis specimens is higher than that in their primary gastric cancer and adjacent non-cancerous gastric tissue samples. Each sample was
analyzed in triplicate and normalized to 18S. (B) Expression of MYH9 in primary gastric cancer (Ca) and its adjacent normal stomach tissue (N) by IHC.
(C) Expression of MYH9 in primary gastric cancer (Ca) and its matched lymph node metastasis tissue (M) by IHC.
doi:10.1371/journal.pone.0018409.g006
Table 1. Myosin IIA expression in gastric cancer tissue and matched adjacent normal stomach tissue.
Negative(2) Weak(+) Moderate(++) Strong(+++)P
N 9 of 40(22.5%) 22 of 40(55%) 9 of 40(22.5%) 0 of 40(0)
Ca 3 of 40(7.5%) 20 of 40(50%) 15of 40(37.5%) 2 of 40(5%) ,0.05
Note: Ca-gastric cancer tissue; N-matched adjacent normal stomach tissue.
The expression of myosin IIA is higher in primary gastric cancer tissue compared with matched adjacent normal stomach tissue (P,0.05).
doi:10.1371/journal.pone.0018409.t001
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implicates MYH9 (NMHC-IIA) as a target of SRF, which
contributes to invasion and metastasis in breast cancer [49]. Our
data show that MYH9 is the direct target of let-7f, which inhibited
invasion and metastasis by binding the 39UTR of MYH9, which
resulted in the downregulation of myosin IIA expression.
In conclusion, our study demonstrates that let-7f can suppress
the invasion and metastasis of gastric cancer by directly binding
the 39UTR of MYH9, its target. Though there is still much to
learn about the role of let-7f in gastric cancer tumorigenesis, let-7f
provides us with a new potential target for gastric cancer
treatment.
Supporting Information
Figure S1 The expression of MYH9 in gastric tumor
specimens. (A) Expression of MYH9 in primary gastric cancer
(Ca) and its adjacent normal stomach tissue (N) by IHC. (B)
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